Table 2.
Global prevalence of longer duration (more than 3 months) sequelae in 2005 and 2015 for all ages and both sexes combined, with percentage change between 2005 and 2015 for Level 4 causes with prevalence greater than 1%
|
Prevalence (thousands) |
Percentage change (%) |
||
|---|---|---|---|
| 2005 | 2015 | ||
| Permanent caries | 2 045 859 (1 909 845–2 170 355) | 2 344 628 (2 193 751–2 488 741) | 14·6 (13·7 to 15·5)* |
| Tension-type headache | 1 306 390 (1 160 423–1 463 889) | 1 505 892 (1 337 310–1 681 575) | 15·3 (14·0 to 16·6)* |
| Iron-deficiency anaemia | 1 456 387 (1 449 846–1 462 782) | 1 477 531 (1 470 902–1 485 322) | 1·5 (0·9 to 2·1)* |
| Age-related and other hearing loss | 943 504 (886 325–995 403) | 1 210 055 (1 140 224–1 274 665) | 28·3 (27·4 to 29·2)* |
| Migraine | 831 726 (755 991–918 968) | 958 789 (872 109–1 055 631) | 15·3 (14·0 to 16·6)* |
| Genital herpes | 716 115 (626 987–817 387) | 845 826 (736 724–968 066) | 18·1 (16·4 to 19·9)* |
| Refraction and accommodation disorders | 672 165 (649 969–694 024) | 819 307 (789 917–848 059) | 21·9 (20·5 to 23·2)* |
| Ascariasis | 854 489 (790 000–924 895) | 761 894 (682 558–861 031) | −10·8 (−22·5 to 2·5) |
| G6PD trait | 663 704 (625 032–703 799) | 728 549 (676 735–781 534) | 9·8 (7·9 to 11·4)* |
| Acne vulgaris | 605 008 (568 577–642 061) | 632 741 (595 242–671 249) | 4·6 (3·5 to 5·6)* |
| Other skin and subcutaneous diseases | 492 883 (480 852–505 426) | 605 036 (589 500–619 676) | 22·8 (22·1 to 23·4)* |
| Deciduous caries | 534 122 (449 525–635 866) | 558 028 (462 649–669 027) | 4·5 (2·3 to 6·1)* |
| Low back pain | 460 164 (444 680–477 119) | 539 907 (521 449–559 556) | 17·3 (16·5 to 18·2)* |
| Periodontal diseases | 428 784 (372 953–498 682) | 537 506 (465 114–625 889) | 25·4 (24·1 to 26·5)* |
| Fungal skin diseases | 434 604 (395 512–475 904) | 492 373 (448 951–538 232) | 13·3 (12·5 to 14·1)* |
| Trichuriasis | 473 399 (443 689–505 928) | 463 652 (426 621–502 939) | −2·1 (−12·0 to 9·0) |
| Diabetes | 333 325 (310 773–355 510) | 435 328 (404 736–468 562) | 30·6 (28·0 to 33·0)* |
| Premenstrual syndrome | 391 207 (375 009–407 896) | 430 697 (410 841–450 494) | 10·1 (7·9 to 11·8)* |
| Hookworm disease | 462 111 (430 885–495 596) | 428 246 (394 486–468 292) | −7·3 (−16·9 to 3·5) |
| Sickle-cell trait | 338 756 (318 736–378 582) | 404 566 (381 223–448 155) | 19·4 (18·3 to 20·3)* |
| Asthma | 327 097 (296 406–358 060) | 358 198 (323 134–393 466) | 9·5 (7·6 to 11·6)* |
| Neck pain | 295 532 (258 878–338 138) | 358 007 (313 408–409 411) | 21·1 (19·0 to 23·3)* |
| Hepatitis B | 293 745 (284 478–303 036) | 343 251 (330 541–357 195) | 16·9 (15·3 to 18·4)* |
| Other musculoskeletal disorders | 283 317 (254 135–315 519) | 342 068 (305 431–385 147) | 20·7 (17·5 to 24·0)* |
| Urolithiasis | 259 567 (238 100–281 892) | 318 763 (290 695 349 154) | 22·8 (20·8 to 24·9)* |
| Thalassaemias trait | 252 798 (247 008–259 972) | 279 451 (272 819–287 357) | 10·5 (10·1 to 11·0)* |
| Malaria | 207 773 (186 530–230 942) | 278 961 (240 158–320 921) | 34·3 (26·8 to 42·3)* |
| Edentulism and severe tooth loss | 216 473 (207 563–226 331) | 275 619 (264 201–288 252) | 27·3 (26·9 to 27·7)* |
| Anxiety disorders | 232 597 (204 165–264 445) | 267 202 (234 064–306 318) | 14·9 (13·0 to 16·8)* |
| Other sense organ diseases | 214 761 (207 401–222 622) | 266 346 (257 047–276 383) | 24·0 (23·1 to 24·9)* |
| Schistosomiasis | 329 773 (297 093–367 878) | 252 340 (211 032–321 081) | −23·5 (−32·5 to −4·4)* |
| G6PD deficiency | 231 109 (205 067–259 769) | 247 074 (209 307–286 713) | 6·9 (1·4 to 11·9)* |
| Dermatitis | 215 260 (199 590–230 536) | 245 291 (227 283–262 752) | 14·0 (13·2 to 14·8)* |
| Osteoarthritis | 178 665 (173 558–184 053) | 237 369 (230 336–244 648) | 32·9 (31·9 to 33·8)* |
| Major depressive disorder | 183 434 (163 947–206 420) | 216 047 (192 863–243 319) | 17·8 (16·6 to 19·0)* |
| Scabies | 191 482 (166 101–223 739) | 204 152 (177 534–237 466) | 6·6 (4·0 to 9·5)* |
| Viral skin diseases | 161 167 (152 218–170 651) | 174 843 (165 156–185 072) | 8·5 (8·0 to 9·0)* |
| Chronic obstructive pulmonary disease | 149 115 (137 380–160 739) | 174 483 (160 205–188 952) | 17·0 (15·1 to 19·0)* |
| Genital prolapse | 137 383 (121 623–154 875) | 161 679 (142 335–182 566) | 17·7 (15·2 to 20·0)* |
| Gastritis and duodenitis | 135 993 (134 420–137 351) | 157 060 (154 055–160 141) | 15·5 (12·9 to 17·9)* |
| Peripheral vascular disease | 115 109 (101 439–131 405) | 154 651 (136 318–176 211) | 34·4 (33·4 to 35·2)* |
| Uterine fibroids | 126 797 (120 900–133 050) | 151 115 (144 147–158 477) | 19·2 (18·8 to 19·5)* |
| Hepatitis C | 120 457 (108 080–133 129) | 142 123 (126 978–157 045) | 18·0 (16·7 to 19·2)* |
| Other mental and substance use disorders | 107 895 (107 213–108 449) | 128 178 (127 512–128 877) | 18·8 (17·9 to 19·7)* |
| Iodine deficiency | 103 701 (93 441–116 438) | 110 920 (100 337–125 253) | 7·0 (4·7 to 9·4)* |
| Ischaemic heart disease | 87 511 (80 133–96 170) | 110 193 (100 332–121 427) | 25·9 (24·6 to 27·2)* |
| Benign prostatic hyperplasia | 80 684 (70 338–90 853) | 104 625 (90 730–118 244) | 29·7 (27·5 to 32·0)* |
| Dysthymia | 86 812 (74 974–99 103) | 104 106 (90 398–118 969) | 19·9 (18·4 to 21·5)* |
| Chronic kidney disease due to diabetes | 79 184 (68 481–90 737) | 100 824 (86 923–115 652) | 27·3 (24·9 to 29·9)* |
| Chronic kidney disease due to other causes | 74 917 (64 012–86 576) | 94 553 (81 142–109 371) | 26·2 (24·2 to 28·3)* |
| Idiopathic developmental intellectual disability | 82 996 (47 588–117 109) | 92 074 (52 280–130 411) | 10·9 (9·5 to 11·9)* |
| Other cardiovascular and circulatory diseases | 72 772 (68 090–77 763) | 90 348 (84 711–96 659) | 24·2 (22·7 to 25·5)* |
| Otitis media | 83 022 (73 657–93 266) | 86 393 (76 374–97 104) | 4·1 (2·7% to 5·5)* |
| Psoriasis | 67 753 (65 107–70 298) | 79 700 (76 691–82 804) | 17·6 (17·0 to 18·3)* |
| Other haemoglobinopathies and haemolytic anaemias | 73 045 (72 600–73 470) | 74 385 (73 898–74 862) | 1·8 (0·9 to 2·7%) |
Data in parentheses are 95% UIs.
*
Percentage changes that are statistically significant.